Vertex Pharmaceuticals
VRTX
479 hedge funds and large institutions have $27.5B invested in Vertex Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 194 increasing their positions, 155 reducing their positions, and 47 closing their positions.
32% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 47
25% more repeat investments, than reductions
Existing positions increased: 194 | Existing positions reduced: 155
1% more funds holding
Funds holding: 474 → 479 (+5)
1% more capital invested
Capital invested by funds: $27.3B → $27.5B (+$279M)
17% less call options, than puts
Call options by funds: $80.4M | Put options by funds: $97.3M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$238M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$220M |
| 3 |
O
OrbiMed
New York
|
-$191M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$139M |
| 5 |
Millennium Management
New York
|
-$79.8M |
VRTX Hedge Fund Activity: Q1 2015 in Review
479 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q1 2015, worth a combined $27.5B — up 1% from $27.3B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new VRTX positions and 47 closed out — a net gain of 15 holders — while 194 added to existing stakes and 155 trimmed.
The largest buyer was Marsico Capital Management, opening a new position worth an estimated $259M. The largest seller was Vanguard Group, cutting an estimated $238M.
- 479 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q1 2015, up from 474 in Q4 2014.
- Funds reported $27.5B of Vertex Pharmaceuticals stock for Q1 2015, up 1% quarter-over-quarter.
- 62 funds opened new Vertex Pharmaceuticals positions in Q1 2015 and 47 closed out, a net change of +15 holders.
- The largest Vertex Pharmaceuticals buyer in Q1 2015 was Marsico Capital Management, an estimated $259M added.
- The largest Vertex Pharmaceuticals seller in Q1 2015 was Vanguard Group, an estimated $238M sold.
Based on aggregated 13F filings for Q1 2015.